Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy
| Autor: | Pilar Jiménez, Rosario Iglesias, Tomás Girbés, Lucía Citores, José Miguel Ferreras |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Models
Molecular endocrine system endoglin (CD105) Cell Survival Protein Conformation Health Toxicology and Mutagenesis media_common.quotation_subject Ribosome-inactivating proteins Endoglina lcsh:Medicine Antineoplastic Agents Transferrin receptor Review Toxicology Lethal Dose 50 chemistry.chemical_compound Immunotoxin Neoplasms Protein biosynthesis Animals Humans transferrin Internalization media_common chemistry.chemical_classification Saúco biology Ribosome-inactivating protein Immunotoxins Sambucus lcsh:R Endoglin Antibodies Monoclonal Inmunotoxinas biology.organism_classification immunotoxin Elder tree Ribosome Inactivating Proteins Type 2 Ricin Biochemistry chemistry Transferrin Proteínas inactivadoras de ribosomas HeLa Cells |
| Zdroj: | UVaDOC. Repositorio Documental de la Universidad de Valladolid Consejo Superior de Investigaciones Científicas (CSIC) UVaDOC: Repositorio Documental de la Universidad de Valladolid Universidad de Valladolid Toxins, Vol 3, Iss 5, Pp 420-441 (2011) Toxins |
| DOI: | 10.3390/toxins3050420 |
| Popis: | Producción Científica The type 2 ribosome-inactivating proteins (RIPs) isolated from some species belonging to the Sambucus genus, have the characteristic that although being even more active than ricin inhibiting protein synthesis in cell-free extracts, they lack the high toxicity of ricin and related type 2 RIPs to intact cells and animals. This is due to the fact that after internalization, they follow a different intracellular pathway that does not allow them to reach the cytosolic ribosomes. The lack of toxicity of type 2 RIPs from Sambucus make them good candidates as toxic moieties in the construction of immunotoxins and conjugates directed against specific targets. Up to now they have been conjugated with either transferrin or anti-CD105 to target either transferrin receptor- or endoglin-overexpressing cells, respectively. Junta de Castilla y León (Junta de Castilla y León (grant VA0150A7 and Grupo de Excelencia GR106) Universidad de Valladolid (grants FISPI04/1279 and BIO39/VA42/10) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|